Arrowhead Pharma (ARWR)

$66.91 +0.09 (0.13%)
Market Cap 9.11B
Revenue (ttm) 829.45M
Net Income (ttm) -1.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -0.20%
Debt to Equity Ratio 0.51
Volume 1,229,647
Avg Vol 2,860,072
Day's Range N/A - N/A
Shares Out 135.88M
Stochastic %K 54%
Beta 1.21
Analysts Strong Sell
Price Target $80.00

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, t...

Industry: Biotechnology
Sector: Healthcare
Phone: 626 304 3400
Fax: 626 304 3401
Address:
177 East Colorado Boulevard, Suite 700, Pasadena, United States
skeezbag
skeezbag Jan. 27 at 8:44 PM
$ARWR once again the babysitter (9dema) told arrowhead to come back home
1 · Reply
magross24
magross24 Jan. 27 at 8:39 PM
$ARWR almost 4,000 contracts in March at $45…
0 · Reply
Oxdog
Oxdog Jan. 27 at 8:15 PM
$ARWR Today’s ARO-DIMER-PA announcement looks like one of those “quiet but important” steps rather than a headline mover explaining the somewhat the muted reaction. First dual-gene RNAi (PCSK9 + APOC3) to enter the clinic is actually a pretty big platform statement. Collapsing combo lipid biology into a single siRNA molecule isn’t trivial, and the fact they’re dosing humans tells you the TRiM chemistry held up in NHPs and manufacturing. Awesome. That said, markets don’t pay for “first patient dosed” or preclinical reruns. They’ll wait for human knockdown, safety, and durability before assigning value, especially since both targets are already validated individually. To me this reinforces how ARWR builds: steady, disciplined, platform-first. Not a near-term catalyst, but another brick in the wall for longer-term optionality (and future pipeline compression if dual-RNAi works). Happy to sit through the boredom phase if this is where it’s heading.
1 · Reply
Jschwarma
Jschwarma Jan. 27 at 7:00 PM
$ARWR more volume in my pool. Keep it here for juicy BO premium imo
0 · Reply
BrianRix
BrianRix Jan. 27 at 6:42 PM
$ARWR The trading pattern intradays is always the same. Tired of these little games. We all know what we would still be dirt cheap at 100$. Just a matter of time.
0 · Reply
skeezbag
skeezbag Jan. 27 at 6:08 PM
$ARWR liars at Morgan Stanley out with a note on arwr. More of their oh this is great but we care about this catalyst. Next catalyst achieved, oh this is great but we care about this catalyst......on and on Michael Ulz is a liar but he actually doesn't work for Morgan Stanley, he works for???? Name your BP
1 · Reply
johnnygogogo
johnnygogogo Jan. 27 at 2:56 PM
$ARWR in success, ARO-DIMER-PA is going to put most other heart drugs out of business. If you’re here for long term value creation that turns ARWR into a big pharma, this is the one.
0 · Reply
Publicola29
Publicola29 Jan. 27 at 2:11 PM
$ARWR Is WVE the next ARWR?
1 · Reply
Lraifinance
Lraifinance Jan. 27 at 1:48 AM
$ARWR perfect sweet spot for another bounce before earnings. This stock is going to 100$ soon
0 · Reply
CDMO
CDMO Jan. 26 at 7:02 PM
$ARWR
0 · Reply
Latest News on ARWR
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Jan 27, 2026, 7:30 AM EST - 11 hours ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Jan 20, 2026, 4:30 PM EST - 7 days ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 2:06 PM EST - 15 days ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Jan 7, 2026, 11:05 PM EST - 19 days ago

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Jan 7, 2026, 7:30 AM EST - 20 days ago

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Jan 6, 2026, 6:14 PM EST - 21 days ago

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript

Jan 6, 2026, 3:18 PM EST - 21 days ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Jan 6, 2026, 2:58 PM EST - 21 days ago

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.

Jan 6, 2026, 11:26 AM EST - 21 days ago

Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Jan 6, 2026, 10:32 AM EST - 21 days ago

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Jan 6, 2026, 7:30 AM EST - 21 days ago

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Jan 5, 2026, 7:30 AM EST - 22 days ago

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Dec 23, 2025, 7:30 AM EST - 5 weeks ago

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Dec 15, 2025, 4:30 PM EST - 6 weeks ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Dec 8, 2025, 7:30 AM EST - 7 weeks ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Dec 2, 2025, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Dec 1, 2025, 4:00 PM EST - 2 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript

Nov 27, 2025, 7:43 PM EST - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript

Nov 25, 2025, 11:43 PM EST - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Nov 25, 2025, 4:00 PM EST - 2 months ago

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Nov 24, 2025, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

SRPT

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript

Nov 19, 2025, 3:48 AM EST - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript

Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway

Nov 18, 2025, 11:54 PM EST - 2 months ago

Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Nov 18, 2025, 11:52 AM EST - 2 months ago

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

US FDA approves Arrowhead's genetic disorder drug

Nov 18, 2025, 11:21 AM EST - 2 months ago

US FDA approves Arrowhead's genetic disorder drug

Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead

Nov 17, 2025, 10:08 AM EST - 2 months ago

Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Nov 6, 2025, 4:30 PM EST - 2 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Nov 4, 2025, 7:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Oct 21, 2025, 7:30 AM EDT - 3 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Oct 7, 2025, 7:30 AM EDT - 4 months ago

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Sep 29, 2025, 7:11 AM EDT - 4 months ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ASMB ATRA CORT

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Sep 11, 2025, 7:30 AM EDT - 4 months ago

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 2:55 PM EDT - 4 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Sep 10, 2025, 7:30 AM EDT - 4 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 9, 2025, 1:42 PM EDT - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:35 PM EDT - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript)

Sep 3, 2025, 4:00 PM EDT - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript)

Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place

Sep 3, 2025, 1:15 PM EDT - 5 months ago

Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

Sep 2, 2025, 8:13 AM EDT - 5 months ago

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

NVS

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Sep 2, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Aug 27, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Aug 13, 2025, 4:10 PM EDT - 5 months ago

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript

Aug 8, 2025, 8:48 PM EDT - 6 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Aug 7, 2025, 4:01 PM EDT - 6 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Aug 1, 2025, 6:30 AM EDT - 6 months ago

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

Jul 28, 2025, 7:30 AM EDT - 6 months ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

SRPT

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Jul 23, 2025, 8:00 AM EDT - 6 months ago

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

Jul 22, 2025, 1:30 PM EDT - 6 months ago

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

SRPT

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Jul 21, 2025, 4:01 PM EDT - 6 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Jul 8, 2025, 7:30 AM EDT - 7 months ago

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

skeezbag
skeezbag Jan. 27 at 8:44 PM
$ARWR once again the babysitter (9dema) told arrowhead to come back home
1 · Reply
magross24
magross24 Jan. 27 at 8:39 PM
$ARWR almost 4,000 contracts in March at $45…
0 · Reply
Oxdog
Oxdog Jan. 27 at 8:15 PM
$ARWR Today’s ARO-DIMER-PA announcement looks like one of those “quiet but important” steps rather than a headline mover explaining the somewhat the muted reaction. First dual-gene RNAi (PCSK9 + APOC3) to enter the clinic is actually a pretty big platform statement. Collapsing combo lipid biology into a single siRNA molecule isn’t trivial, and the fact they’re dosing humans tells you the TRiM chemistry held up in NHPs and manufacturing. Awesome. That said, markets don’t pay for “first patient dosed” or preclinical reruns. They’ll wait for human knockdown, safety, and durability before assigning value, especially since both targets are already validated individually. To me this reinforces how ARWR builds: steady, disciplined, platform-first. Not a near-term catalyst, but another brick in the wall for longer-term optionality (and future pipeline compression if dual-RNAi works). Happy to sit through the boredom phase if this is where it’s heading.
1 · Reply
Jschwarma
Jschwarma Jan. 27 at 7:00 PM
$ARWR more volume in my pool. Keep it here for juicy BO premium imo
0 · Reply
BrianRix
BrianRix Jan. 27 at 6:42 PM
$ARWR The trading pattern intradays is always the same. Tired of these little games. We all know what we would still be dirt cheap at 100$. Just a matter of time.
0 · Reply
skeezbag
skeezbag Jan. 27 at 6:08 PM
$ARWR liars at Morgan Stanley out with a note on arwr. More of their oh this is great but we care about this catalyst. Next catalyst achieved, oh this is great but we care about this catalyst......on and on Michael Ulz is a liar but he actually doesn't work for Morgan Stanley, he works for???? Name your BP
1 · Reply
johnnygogogo
johnnygogogo Jan. 27 at 2:56 PM
$ARWR in success, ARO-DIMER-PA is going to put most other heart drugs out of business. If you’re here for long term value creation that turns ARWR into a big pharma, this is the one.
0 · Reply
Publicola29
Publicola29 Jan. 27 at 2:11 PM
$ARWR Is WVE the next ARWR?
1 · Reply
Lraifinance
Lraifinance Jan. 27 at 1:48 AM
$ARWR perfect sweet spot for another bounce before earnings. This stock is going to 100$ soon
0 · Reply
CDMO
CDMO Jan. 26 at 7:02 PM
$ARWR
0 · Reply
Lraifinance
Lraifinance Jan. 26 at 2:32 PM
$ARWR
0 · Reply
JFais
JFais Jan. 26 at 1:15 PM
$SRPT- Stat sig on most relevant measures including NSAA (last domino to fall into place) If this weren't currently a battleground stock (ie. Day 1 IPO), where do you think it would revalue up to? (keeping in mind $ARWR siRNA partnership driving future growth + $12B $RNA comp)
2 · Reply
gregg4president
gregg4president Jan. 24 at 1:27 PM
$ARWR See you guys at $100
0 · Reply
johnnygogogo
johnnygogogo Jan. 23 at 11:06 PM
$ARWR must be mag 7 earnings season (ie. when all bios become exit liquidity/ swaps with big tech).
1 · Reply
SuperGreenToday
SuperGreenToday Jan. 23 at 8:42 PM
$ARWR Share Price: $67.51 Contract Selected: Jan 15, 2027 $70 Calls Buy Zone: $16.15 – $19.95 Target Zone: $30.55 – $37.34 Potential Upside: 79% ROI Time to Expiration: 356 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
CDMO
CDMO Jan. 23 at 7:56 PM
$ARWR added some more. A bit overweight on this now but whateveeer
0 · Reply
skeezbag
skeezbag Jan. 23 at 5:58 PM
$ARWR must be a buyout in biotech on Monday. Gotta build the fake premium $XBI
1 · Reply
prismmarketview
prismmarketview Jan. 23 at 4:04 PM
Four next‑generation Alzheimer’s drug candidates drawing attention. Biogen’s (NASDAQ: $BIIB), Arrowhead Pharmaceuticals (NASDAQ: $ARWR), Alnylam Pharmaceuticals (NASDAQ: $ALNY), Alector (NASDAQ: $ALEC) All are aiming to move beyond today’s anti‑amyloid antibodies by more precisely targeting tau, amyloid, and neuroinflammation earlier in the disease course.​ https://prismmarketview.com/four-next-generation-alzheimers-drug-candidates-shaping-the-future-of-treatment/
0 · Reply
TheRealDrWho
TheRealDrWho Jan. 23 at 2:07 PM
$ARWR Apparently LuckyGuy and Tram are dating again
0 · Reply
Lraifinance
Lraifinance Jan. 22 at 5:48 PM
$ARWR look at these options widespread market makers wants to eat the whole pie
0 · Reply
skeezbag
skeezbag Jan. 22 at 5:16 PM
$ARWR price for today was determined days ago
2 · Reply
magross24
magross24 Jan. 22 at 3:31 PM
$ARWR $70 Call Open Interest is 200K…seems there will be a war again this month…
1 · Reply